Selected research
Industry Research
Long-acting Retinal Drugs Industry Research Report 2026
Market perspective
The global Long-acting Retinal Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Long-acting Retinal Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Long-acting Retinal Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Long-acting Retinal Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Long-acting Retinal Drugs include Janssen Pharmaceuticals (Johnson & Johnson), Takeda, Teva Pharmaceutical, Novartis, Merck, Bayer, Alcon Inc., AbbVie Inc. and ThromboGenics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Long-acting Retinal Drugs market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Long-acting Retinal Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Long-acting Retinal Drugs Market by Company
Janssen Pharmaceuticals (Johnson & Johnson)
Takeda
Teva Pharmaceutical
Novartis
Merck
Bayer
Alcon Inc.
AbbVie Inc.
ThromboGenics
Regeneron
Oxurion NV
OncoGene Pharmaceuticals
MeiraGTx Limited
F. Hoffmann-La Roche
Bausch Health Co. Inc.
Allergan
Alimera Sciences Inc.
Long-acting Retinal Drugs Segment by Type
Chemically Synthesized Drugs
Biologics
Natural/Nutritional Supplements
Long-acting Retinal Drugs Segment by Application
Hospital
Clinic
Other
Long-acting Retinal Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Retinal Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Long-acting Retinal Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Retinal Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Long-acting Retinal Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Chemically Synthesized Drugs
- Biologics
- Natural/Nutritional Supplements
Applications
- Hospital
- Clinic
- Other
Companies covered
- Janssen Pharmaceuticals (Johnson & Johnson)
- Takeda
- Teva Pharmaceutical
- Novartis
- Merck
- Bayer
- Alcon Inc.
- AbbVie Inc.
- ThromboGenics
- Regeneron
- Oxurion NV
- OncoGene Pharmaceuticals
- MeiraGTx Limited
- F. Hoffmann-La Roche
- Bausch Health Co. Inc.
- Allergan
- Alimera Sciences Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Long-acting Retinal Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Chemically Synthesized Drugs
- 2.2.3 Biologics
- 2.2.4 Natural/Nutritional Supplements
- 2.3 Long-acting Retinal Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Long-acting Retinal Drugs Breakdown Data by Type
- 3.1 Global Long-acting Retinal Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Long-acting Retinal Drugs Forecasted Market Size by Type (2027-2032)
4 Long-acting Retinal Drugs Breakdown Data by Application
- 4.1 Global Long-acting Retinal Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Long-acting Retinal Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Long-acting Retinal Drugs Market Perspective (2021-2032)
- 5.2 Global Long-acting Retinal Drugs Growth Trends by Region
- 5.2.1 Global Long-acting Retinal Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Long-acting Retinal Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Long-acting Retinal Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Long-acting Retinal Drugs Market Dynamics
- 5.3.1 Long-acting Retinal Drugs Industry Trends
- 5.3.2 Long-acting Retinal Drugs Market Drivers
- 5.3.3 Long-acting Retinal Drugs Market Challenges
- 5.3.4 Long-acting Retinal Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Long-acting Retinal Drugs Players by Revenue
- 6.1.1 Global Top Long-acting Retinal Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Long-acting Retinal Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Long-acting Retinal Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Long-acting Retinal Drugs Head Office and Area Served
- 6.4 Global Long-acting Retinal Drugs Players, Product Type & Application
- 6.5 Global Long-acting Retinal Drugs Manufacturers Established Date
- 6.6 Global Long-acting Retinal Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Long-acting Retinal Drugs Market Size (2021-2032)
- 7.2 North America Long-acting Retinal Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Long-acting Retinal Drugs Market Size by Country (2021-2026)
- 7.4 North America Long-acting Retinal Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Long-acting Retinal Drugs Market Size (2021-2032)
- 8.2 Europe Long-acting Retinal Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Long-acting Retinal Drugs Market Size by Country (2021-2026)
- 8.4 Europe Long-acting Retinal Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Long-acting Retinal Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Long-acting Retinal Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Long-acting Retinal Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Long-acting Retinal Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Long-acting Retinal Drugs Market Size (2021-2032)
- 10.2 South America Long-acting Retinal Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Long-acting Retinal Drugs Market Size by Country (2021-2026)
- 10.4 South America Long-acting Retinal Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Long-acting Retinal Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Long-acting Retinal Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Long-acting Retinal Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Long-acting Retinal Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Janssen Pharmaceuticals (Johnson & Johnson)
- 12.1.1 Janssen Pharmaceuticals (Johnson & Johnson) Company Information
- 12.1.2 Janssen Pharmaceuticals (Johnson & Johnson) Business Overview
- 12.1.3 Janssen Pharmaceuticals (Johnson & Johnson) Revenue in Long-acting Retinal Drugs Business (2021-2026)
- 12.1.4 Janssen Pharmaceuticals (Johnson & Johnson) Long-acting Retinal Drugs Product Portfolio
- 12.1.5 Janssen Pharmaceuticals (Johnson & Johnson) Recent Developments
- 12.2 Takeda
- 12.2.1 Takeda Company Information
- 12.2.2 Takeda Business Overview
- 12.2.3 Takeda Revenue in Long-acting Retinal Drugs Business (2021-2026)
- 12.2.4 Takeda Long-acting Retinal Drugs Product Portfolio
- 12.2.5 Takeda Recent Developments
- 12.3 Teva Pharmaceutical
- 12.3.1 Teva Pharmaceutical Company Information
- 12.3.2 Teva Pharmaceutical Business Overview
- 12.3.3 Teva Pharmaceutical Revenue in Long-acting Retinal Drugs Business (2021-2026)
- 12.3.4 Teva Pharmaceutical Long-acting Retinal Drugs Product Portfolio
- 12.3.5 Teva Pharmaceutical Recent Developments
- 12.4 Novartis
- 12.4.1 Novartis Company Information
- 12.4.2 Novartis Business Overview
- 12.4.3 Novartis Revenue in Long-acting Retinal Drugs Business (2021-2026)
- 12.4.4 Novartis Long-acting Retinal Drugs Product Portfolio
- 12.4.5 Novartis Recent Developments
- 12.5 Merck
- 12.5.1 Merck Company Information
- 12.5.2 Merck Business Overview
- 12.5.3 Merck Revenue in Long-acting Retinal Drugs Business (2021-2026)
- 12.5.4 Merck Long-acting Retinal Drugs Product Portfolio
- 12.5.5 Merck Recent Developments
- 12.6 Bayer
- 12.6.1 Bayer Company Information
- 12.6.2 Bayer Business Overview
- 12.6.3 Bayer Revenue in Long-acting Retinal Drugs Business (2021-2026)
- 12.6.4 Bayer Long-acting Retinal Drugs Product Portfolio
- 12.6.5 Bayer Recent Developments
- 12.7 Alcon Inc.
- 12.7.1 Alcon Inc. Company Information
- 12.7.2 Alcon Inc. Business Overview
- 12.7.3 Alcon Inc. Revenue in Long-acting Retinal Drugs Business (2021-2026)
- 12.7.4 Alcon Inc. Long-acting Retinal Drugs Product Portfolio
- 12.7.5 Alcon Inc. Recent Developments
- 12.8 AbbVie Inc.
- 12.8.1 AbbVie Inc. Company Information
- 12.8.2 AbbVie Inc. Business Overview
- 12.8.3 AbbVie Inc. Revenue in Long-acting Retinal Drugs Business (2021-2026)
- 12.8.4 AbbVie Inc. Long-acting Retinal Drugs Product Portfolio
- 12.8.5 AbbVie Inc. Recent Developments
- 12.9 ThromboGenics
- 12.9.1 ThromboGenics Company Information
- 12.9.2 ThromboGenics Business Overview
- 12.9.3 ThromboGenics Revenue in Long-acting Retinal Drugs Business (2021-2026)
- 12.9.4 ThromboGenics Long-acting Retinal Drugs Product Portfolio
- 12.9.5 ThromboGenics Recent Developments
- 12.10 Regeneron
- 12.10.1 Regeneron Company Information
- 12.10.2 Regeneron Business Overview
- 12.10.3 Regeneron Revenue in Long-acting Retinal Drugs Business (2021-2026)
- 12.10.4 Regeneron Long-acting Retinal Drugs Product Portfolio
- 12.10.5 Regeneron Recent Developments
- 12.11 Oxurion NV
- 12.11.1 Oxurion NV Company Information
- 12.11.2 Oxurion NV Business Overview
- 12.11.3 Oxurion NV Revenue in Long-acting Retinal Drugs Business (2021-2026)
- 12.11.4 Oxurion NV Long-acting Retinal Drugs Product Portfolio
- 12.11.5 Oxurion NV Recent Developments
- 12.12 OncoGene Pharmaceuticals
- 12.12.1 OncoGene Pharmaceuticals Company Information
- 12.12.2 OncoGene Pharmaceuticals Business Overview
- 12.12.3 OncoGene Pharmaceuticals Revenue in Long-acting Retinal Drugs Business (2021-2026)
- 12.12.4 OncoGene Pharmaceuticals Long-acting Retinal Drugs Product Portfolio
- 12.12.5 OncoGene Pharmaceuticals Recent Developments
- 12.13 MeiraGTx Limited
- 12.13.1 MeiraGTx Limited Company Information
- 12.13.2 MeiraGTx Limited Business Overview
- 12.13.3 MeiraGTx Limited Revenue in Long-acting Retinal Drugs Business (2021-2026)
- 12.13.4 MeiraGTx Limited Long-acting Retinal Drugs Product Portfolio
- 12.13.5 MeiraGTx Limited Recent Developments
- 12.14 F. Hoffmann-La Roche
- 12.14.1 F. Hoffmann-La Roche Company Information
- 12.14.2 F. Hoffmann-La Roche Business Overview
- 12.14.3 F. Hoffmann-La Roche Revenue in Long-acting Retinal Drugs Business (2021-2026)
- 12.14.4 F. Hoffmann-La Roche Long-acting Retinal Drugs Product Portfolio
- 12.14.5 F. Hoffmann-La Roche Recent Developments
- 12.15 Bausch Health Co. Inc.
- 12.15.1 Bausch Health Co. Inc. Company Information
- 12.15.2 Bausch Health Co. Inc. Business Overview
- 12.15.3 Bausch Health Co. Inc. Revenue in Long-acting Retinal Drugs Business (2021-2026)
- 12.15.4 Bausch Health Co. Inc. Long-acting Retinal Drugs Product Portfolio
- 12.15.5 Bausch Health Co. Inc. Recent Developments
- 12.16 Allergan
- 12.16.1 Allergan Company Information
- 12.16.2 Allergan Business Overview
- 12.16.3 Allergan Revenue in Long-acting Retinal Drugs Business (2021-2026)
- 12.16.4 Allergan Long-acting Retinal Drugs Product Portfolio
- 12.16.5 Allergan Recent Developments
- 12.17 Alimera Sciences Inc.
- 12.17.1 Alimera Sciences Inc. Company Information
- 12.17.2 Alimera Sciences Inc. Business Overview
- 12.17.3 Alimera Sciences Inc. Revenue in Long-acting Retinal Drugs Business (2021-2026)
- 12.17.4 Alimera Sciences Inc. Long-acting Retinal Drugs Product Portfolio
- 12.17.5 Alimera Sciences Inc. Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst